Ghana’s Food and Drugs Authority (FDA) says it has approved the country’s first herbal medicine for Coronavirus clinical trial.
The medicine, Cryptolepis sanguinolenta, is known locally as Nibima. It is developed by researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology (KNUST).
It is seen as a potential treatment for Covid-19.
The medicine received FDA approval after detailed assessment by the national medicine regulatory agency.
In a statement signed by its Chief Executive Officer (CEO), Delese A. Darko, the FDA indicated that “the FDA after detailed assessment of the application gave the requisite regulatory authorisation for the conduct of the trial as per the mandate outlined under Part 8 (Section150-116) of the Public Health Act 2012 (Acct 851).”
FDA has legal mandate to regulate clinical trials of drugs, herbal products, cosmetics or medical devices.
It indicated that initial laboratory studies conducted on the medicine by the KNUST research team pointed in the direction of possible clinical benefits for Covid-19 treatment.
Ghana has recorded some 416 coronavirus deaths and over 65,000 confirmed cases of coronavirus.
The government of Ghana has reintroduced restrictions including the ban on holding weddings, parties, funerals and concerts, as well as the closure of beaches and cinemas as a way of controlling the spread of coronavirus.
Below is the FDA statement
Do you have a story, video for African entertainment? WhatsApp Us on +233543452542
You can also email us at info@AfricanEntertainment.com
